Gram-negative ESKAPE pathogens (Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.) are responsible for increases in antimicrobial-resistant infections worldwide. We determined in vitro susceptibilities to eight parenteral antimicrobial agents using Clinical and Laboratory Standards Institute broth microdilution methodology for Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal infections (IAIs) (n=3052) and urinary tract infections (UTIs) (n=1088) in 11 Asia-Pacific countries/regions from 2013 to 2015. Amikacin (98.3, 96.4 %), imipenem (97.1, 95.5 %) and ertapenem (95.3, 93.2 %) demonstrated the highest rates of susceptibility for isolates of K. pneumoniae from IAI and UTI, respectively, whereas susceptibility to advanced-generation cephalosporins was <84 and <71 %, respectively. K. pneumoniae with an extended-spectrum b-lactamase-positive phenotype were more common in UTI (27.1 %) than IAI (16.2 %). Imipenem and amikacin were the most active agents against extended-spectrum b-lactamasepositive K. pneumoniae from IAI (95.1, 91.8 %) and UTI (94.9, 92.3 %), respectively, whereas <54 % were susceptible to piperacillin-tazobactam. Against Enterobacter spp. and P. aeruginosa, amikacin demonstrated the highest rates of susceptibility for isolates from IAI (99.7, 95.5 %) and UTI (90.9, 91.5 %), respectively. K. pneumoniae, Enterobacter spp. and P. aeruginosa from urine demonstrated lower susceptibility to levofloxacin (74.1, 81.8 and 73.8 %) than from IAI (87.6, 91.8 and 85.4 %). For A. baumannii, rates of susceptibility to all agents tested were <43 %. We conclude that the studied Gram-negative ESKAPE pathogens demonstrated reduced susceptibility to commonly prescribed advanced-generation cephalosporins, piperacillin-tazobactam and levofloxacin, while amikacin and carbapenems were the most active. Ongoing surveillance to monitor evolving resistance trends and the development of novel antimicrobial agents with potent activity against Gramnegative ESKAPE pathogens are mandatory.
INTRODUCTION
The acronym ESKAPE was first used in 2008 to demarcate a group of pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.) that were causing significant and increasing numbers of hospitalacquired infections and that had the propensity to 'escape' the effects of currently marketed antimicrobial agents [1, 2] . The incidence of ESKAPE pathogens as aetiologic agents of human disease has increased with time, and infections resulting from antimicrobial-resistant ESKAPE pathogens have been observed to be associated with poorer patient outcomes than infections arising from similar antimicrobial-susceptible isolates [2] . Presently, ESKAPE pathogens are primarily associated with nosocomially acquired infections [2] . However, there is growing trepidation that this group of multidrug-resistant pathogens will successfully spread to community settings given the increasing numbers of immunosuppressed and critically ill patients initially seeking care in hospitals who return to the community once treated and/or stable. Importantly, patients infected with antimicrobial-resistant ESKAPE pathogens more frequently receive inappropriate empirical antimicrobial therapy than do patients with antimicrobial-susceptible pathogens, leading to higher case fatality rates and opportunities for spread to neighbouring patients [3] . The strongest predictor of mortality in a critically ill patient infected with an antimicrobial-resistant ESKAPE pathogen is the delay in time to appropriate antimicrobial therapy [2] . Gram-negative ESKAPE pathogens (K. pneumoniae, A. baumannii, P. aeruginosa and Enterobacter spp.) are particularly concerning because their multidrug-resistant phenotypes frequently present clinicians with few therapeutic options [1, 2, 4, 5] . Equally concerning is the lack of new antimicrobial agents in the development pipeline to treat multidrug-resistant Gram-negative ESKAPE pathogens [5] .
The availability of current resistance data, generated through ongoing antimicrobial susceptibility surveillance, is important for the medical community, drug developers and governmental policymakers, among others. The aim of the current study is to satisfy this need by reporting on resistance patterns of recent Gram-negative ESKAPE pathogens isolated from hospitalized patients with intraabdominal infections (IAIs) and urinary tract infections (UTIs) in 11 Asia-Pacific countries/regions from 2013 to 2015. Isolates were collected by the Study for Monitoring Antimicrobial Resistance Trends (SMART) global surveillance programme which was established in 2002 to monitor in vitro antimicrobial susceptibility profiles of clinical isolates of aerobic and facultative Gram-negative bacilli collected worldwide from patients with IAIs against a uniform list of parenteral antimicrobial agents [6] [7] [8] . The SMART study was expanded in 2009 to include Gramnegative bacilli from patients with UTIs [9] . Because ESKAPE pathogens can account for the majority of antimicrobial resistance encountered in the nosocomial setting [1, 4] , surveillance describing resistance profiles of these organisms provides an important point prevalence measure of regional antimicrobial resistance present in community and hospitalized patients and has the potential to detect potential resistance trends and geographic diversity over time [7, 9, 10] . In addition, surveillance data describing susceptibility patterns may provide guidance in choosing empirical antimicrobial therapy for selected infections and patient types [e.g. intensive care unit (ICU), non-ICU] and may stimulate antimicrobial stewardship efforts [7, 9, 10] .
METHODS

Bacterial isolates
General isolate collection protocols for the SMART surveillance programme have been previously described [6] . For the current study, the SMART surveillance programme collected 10 667 isolates of Gram-negative bacilli from hospitalized patients with IAIs (n=7173) and UTIs (n=3494) from 37 clinical laboratories in 11 countries/regions in the Asia-Pacific region (Australia, Hong Kong, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam; isolates from mainland China and India are not included in the dataset) from 2013 to 2015. Antimicrobial susceptibility testing Antimicrobial susceptibility testing was performed at IHMA using the Clinical and Laboratory Standards Institute broth microdilution method [11, 12] with custom dehydrated panels manufactured by MicroScan (Beckman Coulter) in 2013 and 2014 and by Trek Diagnostic Systems (Thermo Scientific) in 2015. All isolates were tested against amikacin, cefepime, ceftazidime, ceftriaxone, ertapenem, imipenem, levofloxacin and piperacillin-tazobactam. The antimicrobial agents tested by the SMART global surveillance programme are those recommended by the Surgical Infection Society and the Infectious Diseases Society of America in their guidelines for the diagnosis and management of complicated IAIs [13] and may also potentially be prescribed for hospitalized patients with UTIs attributable to Gram-negative ESKAPE pathogens. K. pneumoniae were screened for an extended-spectrum b-lactamase (ESBL) phenotype (ceftazidime or cefotaxime MIC of >1 µg ml À1 ) and confirmed as ESBL producers using combination clavulanic acid-based testing, according to the Clinical and Laboratory Standards Institute method [11] .
Statistical analysis
Differences in susceptibility and ESBL rates between IAI and UTI isolates as well as between isolates from ICU and non-ICU wards were assessed for statistical significance using the Fisher's exact test. P<0.05 was considered significant; 95 % confidence intervals were calculated using the adjusted Wald method.
RESULTS
Susceptibility and ESBL rates of K. pneumoniae In general, K. pneumoniae isolated from UTIs were less susceptible to the antimicrobials tested than were K. pneumoniae isolated from IAIs, and all differences were statistically significant except those for the carbapenems (Tables 1  and 2 Table 2 ). Susceptibility of P. aeruginosa and A. baumannii Amikacin was the most active agent tested against P. aeruginosa isolated from both IAI (95.5 %) and UTI (91.5 %); all other antimicrobial agents were <86 % susceptible with slightly lower rates (P<0.05) observed for isolates from UTIs than from IAIs for the cephalosporins and a larger difference (P<0.0001) between the two sources for levofloxacin, which showed >10 % lower susceptibility for UTI (73.8 %) than for IAI (85.3 %). Rates of susceptibility to all agents tested against A. baumannii were <43 %, and rates were even lower in urinary tract isolates than in isolates from IAIs, with significant differences between the two sources for all agents except amikacin.
Differences between ICU and non-ICU wards
The proportion of Gram-negative ESKAPE pathogens among all Gram-negative isolates collected from hospitalized patients with either an IAI or a UTI was 43.8 % (591/ 1349) for isolates from patients located in an ICU compared with 38.1 % (3549/9318) for isolates from patients in non-ICU settings (P<0.0001, data not shown). ESBL-positive rates of K. pneumoniae were similar (P=0.68) in isolates from ICU patients (both IAIs and UTIs) (20.1 %) and from patients in non-ICU settings (19.1 %) ( Table 3) . In general, rates of susceptibility to the antimicrobial agents tested were similar for isolates from the ICU and non-ICU for ESBLnegative K. pneumoniae and Enterobacter spp. Differences in susceptibilities to several agents were observed for K. pneumoniae overall (with a statistically significant difference for ertapenem), ESBL-positive K. pneumoniae (with a statistically significant difference for imipenem), P. aeruginosa (again with a statistically significant difference for imipenem) and particularly for A. baumannii, where susceptibilities were 7 to 15 % lower for isolates from ICU patients than were isolates from non-ICU patients for all agents tested other than amikacin (with a statistically significant difference for levofloxacin).
Differences in antimicrobial susceptibility and ESBL rates by country Sample sizes were large enough for K. pneumoniae, Enterobacter spp. and P. aeruginosa to examine country-to-country differences. Antimicrobial susceptibility rates showed substantial variation across countries (Table 4) . Rates of susceptibility of K. pneumoniae from hospitalized patients with IAIs or UTIs were lowest in Thailand to advanced-generation cephalosporins (47.7-53.3 %) and piperacillin-tazobactam (67.3 %) and highest in Japan (>90 %) for these agents. Rates of susceptibility of K. pneumoniae to levofloxacin (58.5 %), ertapenem (87.4 %) and imipenem (86.2 %) were lowest in the Philippines. Rates of susceptibility of Enterobacter spp. to advanced-generation cephalosporins (32.4-67.7 %) and piperacillin-tazobactam (61.8 %) were lowest in Singapore (albeit with a small sample size of 34 isolates). Rates of susceptibility of P. aeruginosa to cefepime (63.6 %), ceftazidime (59.1 %), piperacillin-tazobactam (60.6 %) and levofloxacin (57.6 %) were lowest in South Korea. Variability across countries was also seen for ESBL-positive rates. Fig. 1 presents the ESBLpositive rates (with 95 % confidence intervals) among K. pneumoniae from hospitalized patients with IAIs or UTIs in each of the 11 countries and overall. ESBL rates were highest in Thailand (47.7 %) and lowest in Japan (6.6 %).
DISCUSSION
In the current study, Gram-negative ESKAPE pathogens isolated from patients in Asia-Pacific countries from 2013 to 2015 demonstrated reduced in vitro susceptibilities especially to parenteral advanced-generation cephalosporins (cefepime, ceftazidime and ceftriaxone), piperacillin-tazobactam and fluoroquinolones (levofloxacin), with isolates from UTI even less susceptible than isolates from IAI. Previously published surveillance studies have consistently reported that Gram-negative bacilli, including ESKAPE pathogens, isolated from patients in several countries within the Asia-Pacific region generally demonstrate higher rates of antimicrobial resistance than observed in North American and European studies and that the majority of pathogens isolated from ICUs in a number of Asia-Pacific countries are members of the ESKAPE group [7, 9, 10, [14] [15] [16] . In the current study, which tested isolates from 2013 to 2015, the percentage of K. pneumoniae from IAIs that were ESBL positive (16.2 %) was lower than the rate reported in previous SMART studies for the Asia-Pacific region in 2004 (22.9 %) [16] and 2003 (18 %) [7] . This observation is likely the result of the absence of isolates from mainland China and India being included in the current analysis. The percentage of ESBL producers per country in the Asia-Pacific region was formerly reported to demonstrate a broad range from 0 % in New Zealand to 61 % in China in 2009 to 2010 [10] . We continued to see substantial geographic variability, but no country showed as high a rate as China's in 2009 to 2010. Imipenem (94.9-95.1 %) and amikacin (91.8-92.3 %) were the most active agents against ESBL-positive K. pneumoniae in the current study as they have been reported in earlier studies [7, 16] . However, the current study identified 2.8 % to 6.8 % of K. pneumoniae to be carbapenem non-susceptible, compared with a rate of 0.5 % in 2003 [7] , suggesting the emergence of one or more successful clones or the horizontal spread of resistance genes conferring carbapenem resistance. Globally, prior to year 2000, carbapenem resistance in Enterobacteriaceae was rarely encountered. Today, carbapenem resistance in Enterobacteriaceae is not an unusual observation, with resistance most typically arising due to the combination of ESBL and/or AmpC production and porin loss (reduced permeability following one or more chromosomal mutations) or, less commonly, as the result of expression of carbapenemases such as KPC, NDM-1 or VIM [17] .
The percentage of isolates of P. aeruginosa from IAIs in the current study that were susceptible to amikacin, imipenem, cefepime, ceftazidime, piperacillin-tazobactam and levofloxacin were variable but similar to those reported from the SMART study for the Asia-Pacific region from 2003 to 2010 [10] . Liu et al. [10] previously reported that T a i w a n ( 5 5 5 , 9 )
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J a p a n ( 1 5 1 , 4 ) were not significantly different for ceftazidime, cefepime, piperacillin-tazobactam, imipenem, amikacin and levofloxacin; however, significant differences were observed for imipenem susceptibility based on geography, with the greatest susceptibility reported for isolates from New Zealand (97.1 %) and the lowest for isolates from Korea (59.7 %). Susceptibility rates for imipenem in the current study continued to be among the highest for New Zealand (92.0 %), whereas they were lowest in Vietnam (55.2 %).
A. baumannii is an increasingly frequent pathogen in hospitalized patients with IAIs and UTIs [18] . It is intrinsically resistant to several classes of antimicrobial agents, is frequently multidrug resistant, is associated with hospitalized patients in ICUs and intubated patients, demonstrates variability in its geographic prevalence and commonly presents clinicians with therapeutic dilemmas given its resistance profile [18] . In the current study, rates of susceptibility to all agents tested against A. baumannii were <43 %, including amikacin and imipenem. Clearly, novel agents are urgently needed to treat A. baumannii infections. In a recent study by Lob et al. [18] , >70 % of A. baumannii from the Asia-Pacific region from both IAIs and UTIs were multidrug resistant, with higher rates in isolates from patients in ICUs than for isolates from patients outside ICUs. They did not observe significant changes in per cent susceptibility for any of the parenteral agents tested from 2011 to 2014 for isolates from that region [18] . In an earlier study, Liu et al. ceftazidime, cefepime, amikacin and levofloxacin. In contrast, piperacillin-tazobactam and imipenem demonstrated a significant decrease in per cent susceptibility; however, the difference in imipenem susceptibility was geographically dependent, with the greatest susceptibility in isolates from New Zealand (100 %) and the lowest in isolates from China (39.1 %), while reductions in piperacillin-tazobactam activity were more widespread [10] .
It has been suggested that antimicrobial coverage for resistant ESKAPE pathogens be considered when selecting empiric therapy for hospitalized, critically ill patients, particularly transplant patients and those who have previously received antimicrobial therapy [3] . It is essential that any strategy chosen to optimize empiric coverage for ESKAPE pathogens or potentially polymicrobial infections only be applied in appropriate patients in order to minimize exposure to broad-spectrum agents in patients who do not require these regimens. Of interest, in the current study, we observed few statistically significant differences in the susceptibilities of Gram-negative ESKAPE pathogens isolated from patients in ICU and non-ICU settings in the AsiaPacific region (Table 3) . Our findings contrast with the frequently lower rates of antimicrobial susceptibility observed in enteric pathogens isolated from ICU patients compared with non-ICU patients in other studies and regions [19] [20] [21] .
Nevertheless, it appears useful to take into account patient location within the hospital when selecting agents for empiric therapy in the Asia-Pacific region, as ESKAPE pathogens were significantly more common in specimens from ICU patients and carbapenems were typically significantly less active in isolates from ICUs.
Limitations of the current study include that the SMART surveillance programme collects isolates from only a few sites in some countries, that participating sites may not be uniformly distributed in each country, that the number of isolates collected at each site may be variable and that the classification of isolates by patient location in a hospital may be imperfect as patients may move between wards during a single admission. In addition, outbreaks of antimicrobial-resistant strains and infection control interventions at individual hospital sites are not accounted for, and even though isolates in surveillance studies are limited to one per species per patient, there is also the potential for resistant isolates to be overrepresented as complicated patients who receive multiple antimicrobial agents may be more likely to be sampled than acutely ill patients who have not recently previously received antimicrobial therapy. Even with all these caveats, surveillance programmes such as SMART provide a helpful overview of general antimicrobial resistance patterns among pathogens causing human infections.
CONCLUSIONS
We conclude that Gram-negative ESKAPE pathogens isolated from patients in Asia-Pacific countries from 2013 to 2015 demonstrate reduced in vitro susceptibilities to parenteral advanced-generation cephalosporins (cefepime, ceftazidime and ceftriaxone), piperacillin-tazobactam and fluoroquinolones (levofloxacin), even in non-ICU wards, which suggests that empiric treatment with these agents carries risk for patients. Rates of ESBL-positive K. pneumoniae were 27.1 % for isolates from UTIs and 16.2 % for isolates from IAIs, and 2.8 % to 6.8 % of K. pneumoniae are now carbapenem non-susceptible, compared with a rate of 0.5 % in 2003 [7] . Novel antimicrobial agents with dependable activity against Gram-negative ESKAPE pathogens have been slow to appear. Therefore, efforts need to focus on strategies to prevent initial development of infections and to decrease delays in the time to appropriate antimicrobial therapy for hospitalized patients while at the same time attempting to limit unnecessary use of broad-spectrum antimicrobials. Publication of studies describing successful clinical interventions to decrease the prevalence of resistance is also needed [2, 4] . Continued surveillance is critical because it provides guidance for empiric antimicrobial agent selection by identifying the most common pathogens associated with specific infection types and characterizing their antimicrobial susceptibility profiles. The data in this paper highlight the challenges associated with selection of appropriate antimicrobial therapy for hospitalized patients, particularly those patients present in ICUs who develop an infection due to a Gram-negative ESKAPE pathogen.
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